The FDA has issued a Complete Response Letter for Mylan and Biocon’s pegfilgrastim biosimilar, MYL-1401H, referenced on Neulasta.
Indian drug maker Biocon announced today that the FDA has issued a Complete Response Letter (CRL) for Biocon—Mylan’s proposed pegfilgrastim biosimilar, MYL-1401H, referenced on Neulasta.
Pegfilgrastim is a long-acting version of filgrastim; while biosimilars of filgrastim are approved in the United States and in the European Union, to date, no biosimilar developer had been successful in gaining regulatory clearance in either region for the more complex long-acting drug. One of the challenges of developing pegfilgrastim has been the presence of the polyethylene glycol (PEG) molecule, which is bonded to filgrastim and slows the rate at which the drug is metabolized.
Biocon indicates that the CRL for the drug relates to “data from facility requalification activities” after recent modifications to its manufacturing plant, and that the CRL did not raise questions concerning the drug’s biosimilarity, pharmacokinetic or pharmacodynamic data, clinical data, or immunogenicity. Biocon—Mylan had previously withdrawn an application for the same drug from the European Medicines Agency (EMA) after a French National Agency for Medicines and Health Products Safety (ANSM) inspection that found 35 deficiencies—11 of them major—in Biocon’s manufacturing practices at its Bangalore manufacturing plant. While the companies plan to resubmit their application to the EMA after a re-inspection of the facility, they have not issued a statement as to when they plan to resubmit a Biologics License Application for the drug to the FDA.
Some stakeholders are hopeful that an eventual approval of a biosimilar pegfilgrastim could produce significant savings for health plans. Molly Billstein Leber, PharmD, BCPS, FASHP, and manager of medication policy and formulary management for the Yale New Haven Health System, told The Center for Biosimilars® in an e-mail, “If insurance companies will reimburse for the biosimilar product, it will be a huge cost savings to the health system. The majority of pegfilgrastim usage is outpatient, so the acceptance rate will be closely tied to reimbursement.”
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.